A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;

NCT04939363 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER_GOV

Sponsor class

Conditions

Richter's Syndrome

Interventions

COMBINATION_PRODUCT: Obinutuzumab with Ibrutinib and Venetoclax

Sponsor

Bnai Zion Medical Center

Collaborators

[object Object]